| Overview |
| bs-12430R-Cy3 |
| DAAM2 Polyclonal Antibody, Cy3 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DAAM2 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 23500 |
| Extracellular matrix |
| DAAM2; DAAM2_HUMAN; Disheveled-associated activator of morphogenesis 2; dishevelled associated activator of morphogenesis 2; dJ90A20A.1; KIAA0381; MGC90515; RP1 278E11.1. |
| DAAM2 is a widely expressed 1,068 amino acid protein that contains one DAD domain, one FH1 domain, one FH2 domain and one GBD domain, through which it may play a role in Wnt/Frizzled-associated signaling events. The gene encoding DAAM2 maps to human chromosome 6, which contains 170 million base pairs and comprises nearly 6% of the human genome. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer, suggesting the presence of a cancer susceptibility locus. Additionally, Porphyria cutanea tarda, Parkinson's disease, Stickler syndrome and a susceptibility to bipolar disorder are all associated with genes that map to chromosome 6. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz